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**PURPOSE:** We sought to study the spectrum of community acquired respiratory virus infections (CARV) among patients with lung transplantation (LT) during the early post-transplant period. We also attempted to evaluate the recipient characteristics associated with development of CARV and its association with bronchiolitis obliterans syndrome (BOS) and mortality at 3 years after LT.

**METHODS:** This was a retrospective chart review study among patients who underwent LT between Jan 1 and December 31, 2013 at the University of Texas Southwestern Medical Center in Dallas TX (n=66, mean age 56.1±13.6 years, M:F 37: 29) . We reviewed the baseline characteristics, pre and post transplant course including the development of CARV during the first year after LT. Diagnosis of CARV was based upon positive respiratory viral polymerase chain reaction on the nasal swab sample among patients with clinical symptoms. We reviewed the strategies used for management of these infections. Development of BOS and mortality at 3 years after LT was recorded. Variables were compared between patients with and without CARV using the Chi-square test and Mann-Whitney U test as appropriate.

**RESULTS:** Nearly a quarter of the patients developed CARV during the first year after LT (n=16, 24.2%). Only one episode of CARV was seen during the first three months with most episodes occurring between 3 and 6 months after transplantation (n=7, 43.8%). Rhinovirus was the most common CARV (n=5) followed by coronavirus (n=4) and respiratory syncytial virus (n=3). Majority of patients reported lower respiratory tract symptoms (14/16) and significant proportion had \>10% decline in spirometry (n=7, 43.8%). Many patients needed hospitalization (n=9) with majority of hospitalized patients requiring inhaled ribavirin and pulse steroids (n=6). All the remaining patients were treated with oral prednisone burst and antibiotics. Patients with CARV were more likely to be females (68.8% vs 36%; OR, 95% CI: 2.81, 1.17-13, p=0.041) and younger in age (median with range: 53.5, 17-67 years vs 60, 23-76 years; p=0.012). There was no association of CARV with the immunosuppressive regimen (azathioprine versus mycophenolate mofetil based), immunoglobulin levels, lymphocyte counts and the Cylex® ImmuKnow assay during the first year. Development of CARV was not associated with an increased risk of BOS (37.5% vs 32%, p=0.76) or mortality (31.3% vs 30%, p=1.0) at 3 years. Kaplan Meier curves did not show any difference in the hazard of BOS among patients with and without CARV (log rank p=0.67).

**CONCLUSIONS:** Development of CARV was common during the first year after LT with risk increasing after the first three months of transplantation. Females and younger patients appear to have an increased risk although the type of immunosuppressive agent or the extent of immunosuppression does not seem to predict its development. Despite significant costs and early morbidity, the risk of BOS or mortality at 3 years post transplant was not increased in this cohort.

**CLINICAL IMPLICATIONS:** Patients with LT, especially young females, may be counseled about the increased risk of CARV beyond the first three months after LT. Aggressive management of CARV may attenuate the risk of early BOS or mortality at three year post transplantation.
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